An international panel of HIV researchers met behind closed doors in Washington DC on June 13 to discuss something almost inconceivable until very recently; whether the eradication of HIV from an infected individual may be within our grasp.
"We're at a point in the disease where we can ask if drugs are potent enough to eradicate the virus," said Robert Schooley, head of the infectious diseases division at the University of Colorado Health Sciences Center in Denver, USA, at the meeting.
Combination Is The Key In contrast to popular public opinion - namely that eradication of HIV will come about as a result of a single breakthrough such as a new drug, vaccine or some other radical approach - it now seems likely that the clever and rational combination of existing and new treatments may hold the answer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze